Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal 10-07-2024, 07:00

ACIC Pharmaceutical Machinery Inc. joins the CNIC to help 7-02-2023, 22:29

PPA Asia and MLP Asia Set to Launch, Bringing World-Class Pro Pickleball to the World’s Most Populous Continent 26-11-2024, 04:25